Publications by authors named "A Charvet-Rumpler"
The real-life retrospective observational study CARMYN aimed at investigating the long-term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse, median age 62 yo) were treated between 02/2014 and 02/2017. Most had been pre-exposed to bortezomib (98.
View Article and Find Full Text PDFIxazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the setting of RRMM. Conducted in France between August 2017 and October 2019, the REMIX study, a non-interventional prospective study, included 376 patients receiving IXA-Rd in second line or later and followed for at least 24 months.
View Article and Find Full Text PDFBackground: The prevalence, prognostic role, and diagnostic value of blood pressure in immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs) remain unclear.
Methods: Using a national cohort of iTTP ( = 368), Shigatoxin-induced hemolytic uremic syndrome ( = 86), atypical hemolytic uremic syndrome ( = 84), and hypertension-related thrombotic microangiopathy ( = 25), we sought to compare the cohort's blood pressure profile to assess its impact on prognosis and diagnostic performances.
Results: Patients with iTTP had lower blood pressure than patients with other TMAs, systolic (130 [interquartile range (IQR) 118-143] vs 161 [IQR 142-180] mmHg) and diastolic (76 [IQR 69-83] vs 92 [IQR 79-105] mmHg, both < 0.
Article Synopsis
- Older patients (≥60 years) with immune thrombotic thrombocytopenic purpura (iTTP) show more severe symptoms and longer diagnosis times compared to younger patients (<60 years), including delirium and renal involvement.
- Short- and mid-term mortality rates are significantly higher in older iTTP patients, and age increases the risk of mortality by 10% for every decade.
- Long-term, older iTTP survivors face a mortality risk more than three times greater than that of non-iTTP elderly individuals, highlighting the severe impact of age on outcomes.
Article Synopsis
- * Despite the positive outcomes, about 49% of patients eventually experience a recurrence of severe ADAMTS13 deficiency, although many respond well to additional rituximab treatments.
- * Long-term follow-up reveals that patients with persistently undetectable ADAMTS13 activity are at a much higher risk for relapse, highlighting the efficacy and favorable risk-benefit ratio of preemptive ritux